Muse cell therapy: 52 questions, answered straight

Muse cells are a rare population of repair cells found in adult human tissue, identified by the surface marker SSEA-3. Published research describes them as pluripotent-like — able to become cells of all three germ layers — and able to travel to injured tissue on their own. They already exist inside your body.

Multilineage-differentiating Stress-Enduring. “Multilineage-differentiating” refers to their ability to become many different cell types. “Stress-Enduring” refers to their survival under conditions that kill most cells — which is how they were discovered.

In bone marrow, peripheral blood, and the connective tissue of many organs, as well as adipose (fat) tissue, skin and umbilical cord tissue. They are endogenous, meaning they occur naturally rather than being manufactured.

The literature describes them as pluripotent-like rather than fully pluripotent. They have differentiated into cells of all three embryonic germ layers in published studies, but unlike true pluripotent cells they have not been observed forming teratomas. That distinction is meaningful, not hedging.

Dr. Mari Dezawa, Professor and Chair of the Division of Stem Cell Biology and Histology at Tohoku University Graduate School of Medicine in Sendai, Japan. She reported them in the Proceedings of the National Academy of Sciences in 2010.

By accident, in 2003. A technician in Dr. Dezawa’s laboratory asked whether a batch of severely stressed mesenchymal stem cell cultures should be discarded. Dezawa looked closer and saw that a small number of cells had survived. Seven years of characterisation followed before publication.

Dezawa is correct — Dr. Mari Dezawa. “Dazawa” and “Desawa” are common phonetic misspellings that appear when people have heard the name spoken rather than seen it written. All refer to the same researcher at Tohoku University.

Muse cells are a rare subset found inside mesenchymal stem cell populations — not an alternative to them. MSCs are multipotent and work mainly by releasing signalling molecules. Muse cells are pluripotent-like, reach all three germ layers, migrate to injury via S1P receptors, and both signal and integrate into tissue.

Roughly 1 to 5 percent of a standard mesenchymal stem cell population. That rarity is why enriched Muse cell products cost more to manufacture — isolating a small SSEA-3-positive fraction under cleanroom conditions is far harder than culturing bulk MSCs.

No head-to-head human trial has shown that Muse cell preparations produce better outcomes than standard MSC therapy for any condition. Muse cells have distinct mechanistic advantages, but a more interesting mechanism is not the same as proven better results. Any clinic claiming otherwise has moved past the evidence.

Embryonic stem cells are fully pluripotent but carry teratoma risk and significant ethical objections. Muse cells are collected from adult or perinatal tissue, reach comparable differentiation breadth in published studies, and have not shown tumour formation.

Induced pluripotent stem cells must be genetically reprogrammed to reach a pluripotent state, which adds both risk and manufacturing complexity, and they can form teratomas. Muse cells require no reprogramming — the pluripotent-like behaviour is native to the cell.

No. Exosomes are extracellular vesicles, typically 30 to 150 nanometres, released by cells — not cells themselves. Muse cells release exosomes among their effects, but Muse cell therapy and exosome therapy are different products with different regulatory treatment.

Standard MSC preparations contain some Muse cells, but at a low and usually unverified proportion. That is not equivalent to an enriched, characterised product, and published Muse cell research should not be assumed to apply to unenriched MSC preparations. “Contains Muse cells” and “is an enriched Muse cell product” are different claims.

Three steps: they survive the hostile environment of damaged tissue, migrate toward injury by following a chemical gradient, then repair in two ways — by releasing signalling molecules and by differentiating into replacement tissue. The middle step is what most distinguishes them from standard MSCs.

Stage-specific embryonic antigen 3 — a cell surface marker associated with pluripotency. It is the defining identifier used to isolate Muse cells from mesenchymal stem cell populations, and the figure you should ask any provider to verify on their Certificate of Analysis.

Injured cells release sphingosine-1-phosphate (S1P), creating a concentration gradient strongest at the damage. Muse cells carry S1P receptors, detect that gradient and migrate toward the source. This is why published trials used simple IV infusion rather than direct organ delivery.

Sphingosine-1-phosphate, a lipid signalling molecule released by injured cells. It functions as a distress signal, and it is the mechanism by which Muse cells navigate to sites of tissue damage.

Published studies report differentiation into cells of all three embryonic germ layers — ectoderm (nerve, skin), mesoderm (muscle, bone, cartilage, cardiac) and endoderm (liver and other organs). The literature still describes them as pluripotent-like rather than fully pluripotent.

This is not fully characterised in humans. Published research describes Muse cells remaining at injury sites longer than standard MSCs, which are largely cleared quickly, but precise persistence data in people is limited.

Published studies report a favourable safety profile — no tumour formation, and good tolerability without immunosuppressant drugs. However, trials have involved small numbers of patients with limited long-term follow-up. The accurate description is “encouraging,” not “established.”

No teratoma or tumour formation has been reported across published Muse cell studies. Two factors are cited: they are not genetically reprogrammed, and they appear to lack the unrestrained proliferative capacity that drives teratoma formation in embryonic stem cells and iPSCs.

Reported side effects in published trials have been minimal. Risks common to any IV cell infusion still apply: injection-site reactions, infection risk associated with IV access, transient immune or allergic reactions, and post-infusion fever or flu-like symptoms.

Published Japanese trials administered donor-derived Muse cells without immunosuppressant treatment and reported that this was tolerated. Avoiding immunosuppression matters, since those drugs carry meaningful risks of their own including infection.

Published trials administered donor cells without HLA-matching tests. In conventional allogeneic cell therapy, skipping matching would be expected to cause problems; investigators reported that it did not. If this holds at larger scale it removes a major logistical barrier.

Discuss cell therapy carefully with your physician if you have an active or recent history of cancer, active infection, a significant immune or autoimmune condition, are pregnant or breastfeeding, have significant cardiac, kidney or liver impairment, or have a history of severe allergic reactions to biologic products.

Not extensively. Published cohorts have been small and follow-up periods limited. Multi-year safety data in large populations does not yet exist, and no Phase 3 trials have been completed — which is typically where uncommon safety signals surface.

In practice, usually not the cell type — it’s product quality and provider standards. Unregistered manufacturing facilities, uncharacterised products, missing Certificates of Analysis, no post-thaw viability verification, or administration outside a clinician’s scope of practice introduce risk unrelated to Muse cell biology.

Yes. Human trials have been conducted in Japan using CL2020, an allogeneic Muse cell product, covering acute myocardial infarction, subacute ischemic stroke, ALS, epidermolysis bullosa, cervical spinal cord injury and neonatal hypoxic-ischemic encephalopathy.

An allogeneic Muse cell-based investigational product manufactured by Life Science Institute, Inc., a Mitsubishi Chemical Group company. It is the product used in the Japanese Muse cell clinical trials, and is a separate programme from commercially licensed Muse cell products.

Not proven. A randomised, placebo-controlled trial in subacute ischemic stroke reported a 40% responder rate versus 10% for placebo at 12 weeks on the modified Rankin Scale. That is an encouraging signal, but the trial was small with wide confidence intervals and no Phase 3 study has confirmed it.

A five-patient Phase 2 trial found six monthly infusions well tolerated, but the change in ALSFRS-R score did not reach statistical significance. Three of five patients showed a slowed rate of decline, one worsened, one was unchanged. Any clinic citing this study as evidence of benefit is misrepresenting it.

No. No Phase 3 trials have been completed for any Muse cell indication. Published human research remains early-phase and small.

The completed human trials have been conducted in Japan. No U.S. trial has supported an approved indication.

No published human trials exist for anti-ageing, longevity or cosmetic applications, despite heavy marketing in those categories. Treat any such claim with scepticism, from us or anyone else.

No. As of 2026 there is no FDA-approved Muse cell product for any indication in the United States. Any provider suggesting otherwise is misinforming you.

It is not federally approved. Some states, including Florida, permit licensed physicians to administer certain non-FDA-approved stem cell therapies within defined indications. Federal and state law are in tension on this point, and the FDA has not endorsed these state frameworks.

A Florida law effective July 1, 2025, amending Florida Statutes §458.3245 and §459.0127. It permits licensed Florida MDs and DOs to administer stem cell therapies not approved by the FDA, within their scope of practice, for orthopedics, wound care or pain management.

Only orthopedics, wound care and pain management. Neurological, autoimmune, cardiac, developmental and anti-ageing indications fall entirely outside the statute. A Florida clinic advertising stem cell therapy for stroke recovery, autism or longevity is marketing outside what the law permits.

Cells must come from an FDA-registered facility accredited by the NMDP, WMDA, AABB or AATB, following applicable cGMP standards. Only adult-derived cells are permitted. Physicians must obtain signed informed consent, encourage patients to consult their primary care provider, receive a post-thaw viability report for the lot, and include a specific statutory notice in any advertisement.

No. State law does not preempt federal law. Legal analysts have noted that the Florida statute conflicts directly with the Federal Food, Drug, and Cosmetic Act, and providers operating under it retain federal regulatory exposure.

Not independently. Under SB 1768 only physicians licensed under Chapter 458 (MDs) or Chapter 459 (DOs) are authorised. Delegation and supervision must follow existing scope-of-practice regulations.

Two routes. Intravenous infusion — the cells enter the bloodstream and travel toward damaged tissue on their own. Or direct joint injection — the cells are placed inside a specific joint such as a knee, hip or shoulder.

An IV distributes the cells systemically and relies on their homing ability to reach the target. A joint injection concentrates the entire dose at one location. Which is appropriate depends on your situation, and your physician decides — sometimes both are used.

In published trials, IV infusion took roughly 10 to 15 minutes after the product was thawed and diluted. Joint injection is a short in-office procedure. Neither requires surgery, anaesthesia or a hospital stay.

Neither route involves surgery or general anaesthesia, so recovery expectations differ from a surgical procedure. Your physician will give you specific aftercare guidance based on the route used and your situation.

Published protocols vary. Most involved one to three administrations, though the Japanese ALS trial used six monthly doses. The number depends on the situation and your physician’s clinical assessment — and should be established before you commit financially.

There is no reliable published timeline, and any clinic quoting you a specific one is going beyond the evidence. Outcomes in published trials were measured over weeks to months, and results varied substantially between individuals.

Publicly advertised pricing has ranged from roughly $3,000 to over $50,000. Offshore programmes have historically quoted $25,000–$50,000. Cost depends on cell source, enrichment, dose, number of infusions and what is bundled — always ask for total programme cost, not per-infusion.

Essentially never. Muse cell therapy is not FDA approved for any indication, and U.S. insurers do not generally cover investigational cell therapies. Expect to pay out of pocket.

Because Muse cells are only about 1 to 5 percent of a mesenchymal stem cell population. Isolating, verifying and expanding that rare subpopulation under cleanroom conditions is substantially more complex than culturing bulk MSCs. That’s the legitimate part of any price gap.

Miami Stem Cell is located at 6262 Sunset Drive, Suite 400, South Miami, Florida, and is an authorized provider of Dezawa MuseCells®. Call 305.598.7777 or book a free consultation online.

Authentic Dezawa products originate from MuseCell Innovations’ licensed manufacturing ecosystem and are distributed only through MCI-designated partners, with a Certificate of Analysis on every lot. It matters because published research describes cells made by one specific method — findings don’t automatically transfer to differently manufactured products.

Five: the named manufacturer; proof the facility is FDA-registered under 21 CFR Part 1271; its accreditation (NMDP, WMDA, AABB or AATB); a lot-specific Certificate of Analysis showing cell count, viability and verified SSEA-3 percentage; and the post-thaw viability report. Ask us for all five. Ask every other clinic too.

Guaranteed results. Pricing withheld until you’re in a high-pressure consultation. Time-limited discounts. Vague sourcing like “a leading laboratory.” Citing clinical trials without confirming their product matches. Marketing outside Florida’s authorised indications. And discomfort with any of the questions above.

Yes — free, with no obligation. Its purpose is to establish whether the published evidence supports a regenerative approach in your case, including the possibility that it does not. We’d rather tell you that than take your money.